Computationally-guided multifunctional nanoplatform for enhanced oral delivery and targeted therapy of Helicobacter
Chuqiu Zhang1, Haobo Chen2, Yuanjing Zou2
1School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, 518107, PR China; Institute for Health Innovation & Technology, National University of Singapore, Singapore, 117599, Singapore.
Abstract:
Herbal bioactive ingredients offer considerable promise for the eradication of Helicobacter pylori (H. pylori) due to their inherent non-toxicity, cost-effectiveness, and diverse pharmacological activities. However, their clinical utility is frequently limited by poor oral bioavailability and insufficient accumulation at target sites. In this study, we fabricated a multifunctional nanoplatform for H. pylori-targeted therapy developed through a computationally guided design strategy. Advanced computational methods-including density functional theory (DFT) calculations and molecular dynamics (MD) simulations-were employed to identify tanshinone I (Tan_I) as an optimal herbal candidate for encapsulation within a thiolated fucoidan-polydopamine (PDA-FuSH) nanocarrier. The resulting nanoplatform (T@PDA-FuSH) demonstrated exceptional stability, high drug-loading efficiency, and distinct gastric mucoadhesive properties, attributable to its strong binding affinity for gastric mucin MUC5AC. Furthermore, T@PDA-FuSH exhibited robust bactericidal activity against both standard H. pylori strains and drug-resistant clinical isolates. In vivo evaluation using a H. pylori infected murine model revealed that T@PDA-FuSH effectively reduced H. pylori burden, alleviated inflammatory responses, and promoted the restoration of gastric mucosal integrity. Importantly, this treatment modality preserved the homeostasis of the gastric microbiota, notably enhancing the abundance of beneficial probiotics such as Lactobacillus and Bifidobacterium. Overall, our computationally guided approach provides a novel and promising platform for optimizing the oral delivery of herbal bioactives, significantly enhancing their therapeutic efficacy against H. pylori infection.
More Related Videos
06:12Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
05:23Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drug Delivery: Enteral Route
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
